Q2 EPS Estimates for Alpha Cognition Cut by HC Wainwright

Alpha Cognition Inc. (NASDAQ:ACOG) – Equities researchers at HC Wainwright dropped their Q2 2026 EPS estimates for Alpha Cognition in a note issued to investors on Friday, May 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.33) per share for the quarter, down from their prior forecast of ($0.32). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Alpha Cognition’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Alpha Cognition’s FY2026 earnings at ($1.08) EPS, Q1 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.32) EPS.

ACOG has been the subject of a number of other research reports. Wall Street Zen lowered Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Craig Hallum started coverage on shares of Alpha Cognition in a research note on Friday, April 17th. They set a “buy” rating and a $14.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $16.00.

Alpha Cognition Trading Up 0.5%

Shares of NASDAQ ACOG opened at $5.88 on Wednesday. The stock has a fifty day moving average price of $6.07 and a 200 day moving average price of $5.90. Alpha Cognition has a 12-month low of $4.50 and a 12-month high of $11.54. The company has a market cap of $128.01 million, a P/E ratio of -4.36 and a beta of 2.38.

Alpha Cognition (NASDAQ:ACOG) last issued its earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. The business had revenue of $3.53 million for the quarter, compared to the consensus estimate of $3.42 million. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%.

Institutional Trading of Alpha Cognition

A number of hedge funds have recently made changes to their positions in ACOG. Aristides Capital LLC increased its stake in shares of Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after buying an additional 3,052 shares during the last quarter. Ikarian Capital LLC grew its holdings in Alpha Cognition by 11.6% during the 4th quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock worth $6,866,000 after acquiring an additional 110,000 shares in the last quarter. Sphera Funds Management LTD. increased its holdings in Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock valued at $3,690,000 after buying an additional 228,864 shares during the last quarter. Opaleye Management Inc. raised its stake in Alpha Cognition by 1,698.5% during the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock valued at $13,460,000 after buying an additional 1,955,642 shares in the last quarter. Finally, ACT Capital Management LLC bought a new position in Alpha Cognition during the 4th quarter worth approximately $335,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.